Article
images
Alcon Clareon Vivity IOL receives CE mark, European commercialisation announced
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Unity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular edema
Nicox announces last patient completed final visit in Whistler Phase 3b clinical trial